Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy

• Váldodahkkit: Ping Huang (Dahkki), Jia-huan Huang (Dahkki), Ya-bing Zheng (Dahkki), Wen-ming Cao (Dahkki), Xi-ying Shao (Dahkki), Jun-qing Chen (Dahkki), Yuan Huang (Dahkki), Guang-liang Li (Dahkki), K Sharma (Dahkki), Huan-huan Zhou (Dahkki), Xiao-jia Wang (Dahkki), Hong-chuan Jin (Dahkki), Zhan-hong Chen (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background: Cardiotoxicity associated with the sequential use of anthracyclines followed by trastuzumab is common in adjuvant therapy of patients with HER2-positive early breast cancer (eBC). However, the cardiac safety of trastuzumab concurrent with pegylated liposomal doxorubicin (PLD) is relative...